phenylephrine | Stelfrin injection solution 10 mg / ml 1 ml ampoules 10 pcs.
Special Price
$14.55
Regular Price
$22.00
In stock
SKU
BID877165
Release form
Injection
Injection
Release form
Injection
Pharmacological action
Phenylephrine - alpha 1-adrenostimulator, slightly affecting beta-adrenergic receptors of the heart is not catecholamine, because it contains only one hydroxyl group in the aromatic nucleus.
Causes narrowing of arterioles and increased blood pressure (BP) (with possible reflex bradycardia), but it lasts longer because it is less prone to catechol-O-methyltransferase. Does not cause an increase in minute volume of blood.
After intravenous administration, the effect of the drug develops immediately and lasts for 5-20 minutes.
With subcutaneous and intramuscular administration, the effect of the drug begins in 10-15 minutes and lasts for 1-2 hours after administration.
Contraindications
Hypersensitivity to any of the components of the drug of the disease, accompanied by obstruction of the outflow tract of the left ventricle (severe aortic stenosis, hypertrophic cardiomyopathy)
pheochromocytoma
arterial hypertension of any severity
ventricular fibrillation
glucose-6-phosphate dehydrogenase deficiency
porphyria
acute myocardial hypertension MAO
halotan or cyclopropane anesthesia
pregnancy and lactation
age up to 18 years.
Use during pregnancy and lactation
Adequate and strictly controlled studies of the use of the drug during pregnancy and during breastfeeding have not been conducted.
In animals in late pregnancy, phenylephrine caused fetal growth retardation and stimulated the early onset of labor.
The use of the drug during pregnancy and during breastfeeding is contraindicated.
There are no data on the release of phenylephrine into breast milk.
If you need to use the drug during lactation, breastfeeding should be performed with
Special instructions for
Blood flow monitoring, blood pressure monitoring and at the injection site.
In patients with arterial hypertension, in the case of medical collapse, it is sufficient to maintain systolic blood pressure at a level of 30-40 mm Hg lower than usual. A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment.
Correction of hypovolemia, hypoxia, acidosis and hypercapnia is mandatory before or during shock therapy.
The drug is used with caution in case of arterial hypertension in the pulmonary circulation, hypovolemia, ventricular arrhythmia.
In old age, the number of phenylephrine-sensitive adrenergic receptors decreases.
Composition
1 ml
phenylephrine hydrochloride 10 mg
Excipients:
anhydrous glycerol - 60 mg,
d / i water - up to 1 ml.
Side effects
According to the World Health Organization, unwanted effects are classified according to their frequency of development as follows: very often (? 10% of prescriptions) often (? 1% and <10%) infrequently (? 0.1% and <1 %) rarely (? 0.01% and <0, 1%) very rarely (<0.01%) the frequency is unknown (not enough data to assess the frequency of development).
From the cardiovascular system: rarely - increase or decrease in blood pressure, palpitations, bradycardia, tachycardia, ventricular arrhythmias (especially when used in high doses), angina pectoris frequency unknown - pulmonary edema, cardiac arrest.
From the central nervous system: very rarely - insomnia, nervousness, tremor, anxiety, irritability, confusion, irritability and headache, dizziness, cerebral hemorrhage, paresthesia, weakness.
From the side of the organ of vision: very rarely - pain in the eyes, mydriasis.
From the urinary system: very rarely - dysuria, urinary retention.
From the digestive system: often - nausea, vomiting frequency unknown - increased salivation.
From the respiratory system: rarely - dyspnea.
Allergic reactions: rarely - skin rash, urticaria.
Other: pallor of the skin of the face, sensation of tingling and cooling of the extremities, increased sweating, hyperglycemia.
In some cases, necrosis and the formation of a scab are possible if it gets into the tissue or with subcutaneous injections.
Drug interaction
Phenylephrine reduces the antihypertensive effect of diuretics and antihypertensive drugs, beta-adrenergic blockers and cardiovascular (vascular) blockers (cardiovascular risk) and cardiovascular disorders.
Antipsychotics, phenothiazide derivatives reduce the hypertensive effect of the drug. MAO inhibitors, oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenergic agonists enhance the pressor effect and arrhythmogenic effect of phenylephrine.
Beta-blockers reduce the pacemaker activity of the drug. The use of the drug against the background of the previous use of reserpine can cause the development of a hypertensive crisis due to depletion of catecholamine reserves in adrenergic endings and an increase in sensitivity to adrenergic agonists.
Inhaled anesthetics (including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias (including ventricular fibrillation), since they sharply increase the sensitivity of the myocardium to sympathomimetics. Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect.
Phenylephrine reduces the antianginal effect of nitrates, which, in turn, can reduce the pressor effect of the drug and the risk of arterial hypotension (simultaneous use is allowed depending on the achievement of the desired therapeutic effect).
Thyroid hormones increase (mutually) the effectiveness of the drug and the associated risk of coronary insufficiency (especially with coronary atherosclerosis).
The pressor effect of phenylephrine hydrochloride is increased in patients receiving tricyclic antidepressants.
Phenylephrine, when used concomitantly with digoxin or other cardiac glycosides, increases the risk of heart rhythm disturbances and myocardial infarction. The use of the drug during childbirth to correct arterial hypotension with the use of agents that stimulate labor (vasopressin, ergotamine, ergometrine, methylergometrine) can cause a persistent increase in blood pressure in the postpartum period.
Incompatibility: the drug should not be mixed with other drugs in the same container.
Expiration
3 years
Deystvuyuschee substances
phenylephrine
Prescription conditions from
pharmacies Prescription
dosage form
solution for injection and infusion p7frfrdf14frd4rd14frd63 solution1414frd4f14frd414 injection and infusion
Injection
Pharmacological action
Phenylephrine - alpha 1-adrenostimulator, slightly affecting beta-adrenergic receptors of the heart is not catecholamine, because it contains only one hydroxyl group in the aromatic nucleus.
Causes narrowing of arterioles and increased blood pressure (BP) (with possible reflex bradycardia), but it lasts longer because it is less prone to catechol-O-methyltransferase. Does not cause an increase in minute volume of blood.
After intravenous administration, the effect of the drug develops immediately and lasts for 5-20 minutes.
With subcutaneous and intramuscular administration, the effect of the drug begins in 10-15 minutes and lasts for 1-2 hours after administration.
Contraindications
Hypersensitivity to any of the components of the drug of the disease, accompanied by obstruction of the outflow tract of the left ventricle (severe aortic stenosis, hypertrophic cardiomyopathy)
pheochromocytoma
arterial hypertension of any severity
ventricular fibrillation
glucose-6-phosphate dehydrogenase deficiency
porphyria
acute myocardial hypertension MAO
halotan or cyclopropane anesthesia
pregnancy and lactation
age up to 18 years.
Use during pregnancy and lactation
Adequate and strictly controlled studies of the use of the drug during pregnancy and during breastfeeding have not been conducted.
In animals in late pregnancy, phenylephrine caused fetal growth retardation and stimulated the early onset of labor.
The use of the drug during pregnancy and during breastfeeding is contraindicated.
There are no data on the release of phenylephrine into breast milk.
If you need to use the drug during lactation, breastfeeding should be performed with
Special instructions for
Blood flow monitoring, blood pressure monitoring and at the injection site.
In patients with arterial hypertension, in the case of medical collapse, it is sufficient to maintain systolic blood pressure at a level of 30-40 mm Hg lower than usual. A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment.
Correction of hypovolemia, hypoxia, acidosis and hypercapnia is mandatory before or during shock therapy.
The drug is used with caution in case of arterial hypertension in the pulmonary circulation, hypovolemia, ventricular arrhythmia.
In old age, the number of phenylephrine-sensitive adrenergic receptors decreases.
Composition
1 ml
phenylephrine hydrochloride 10 mg
Excipients:
anhydrous glycerol - 60 mg,
d / i water - up to 1 ml.
Side effects
According to the World Health Organization, unwanted effects are classified according to their frequency of development as follows: very often (? 10% of prescriptions) often (? 1% and <10%) infrequently (? 0.1% and <1 %) rarely (? 0.01% and <0, 1%) very rarely (<0.01%) the frequency is unknown (not enough data to assess the frequency of development).
From the cardiovascular system: rarely - increase or decrease in blood pressure, palpitations, bradycardia, tachycardia, ventricular arrhythmias (especially when used in high doses), angina pectoris frequency unknown - pulmonary edema, cardiac arrest.
From the central nervous system: very rarely - insomnia, nervousness, tremor, anxiety, irritability, confusion, irritability and headache, dizziness, cerebral hemorrhage, paresthesia, weakness.
From the side of the organ of vision: very rarely - pain in the eyes, mydriasis.
From the urinary system: very rarely - dysuria, urinary retention.
From the digestive system: often - nausea, vomiting frequency unknown - increased salivation.
From the respiratory system: rarely - dyspnea.
Allergic reactions: rarely - skin rash, urticaria.
Other: pallor of the skin of the face, sensation of tingling and cooling of the extremities, increased sweating, hyperglycemia.
In some cases, necrosis and the formation of a scab are possible if it gets into the tissue or with subcutaneous injections.
Drug interaction
Phenylephrine reduces the antihypertensive effect of diuretics and antihypertensive drugs, beta-adrenergic blockers and cardiovascular (vascular) blockers (cardiovascular risk) and cardiovascular disorders.
Antipsychotics, phenothiazide derivatives reduce the hypertensive effect of the drug. MAO inhibitors, oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenergic agonists enhance the pressor effect and arrhythmogenic effect of phenylephrine.
Beta-blockers reduce the pacemaker activity of the drug. The use of the drug against the background of the previous use of reserpine can cause the development of a hypertensive crisis due to depletion of catecholamine reserves in adrenergic endings and an increase in sensitivity to adrenergic agonists.
Inhaled anesthetics (including chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias (including ventricular fibrillation), since they sharply increase the sensitivity of the myocardium to sympathomimetics. Ergometrine, ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect.
Phenylephrine reduces the antianginal effect of nitrates, which, in turn, can reduce the pressor effect of the drug and the risk of arterial hypotension (simultaneous use is allowed depending on the achievement of the desired therapeutic effect).
Thyroid hormones increase (mutually) the effectiveness of the drug and the associated risk of coronary insufficiency (especially with coronary atherosclerosis).
The pressor effect of phenylephrine hydrochloride is increased in patients receiving tricyclic antidepressants.
Phenylephrine, when used concomitantly with digoxin or other cardiac glycosides, increases the risk of heart rhythm disturbances and myocardial infarction. The use of the drug during childbirth to correct arterial hypotension with the use of agents that stimulate labor (vasopressin, ergotamine, ergometrine, methylergometrine) can cause a persistent increase in blood pressure in the postpartum period.
Incompatibility: the drug should not be mixed with other drugs in the same container.
Expiration
3 years
Deystvuyuschee substances
phenylephrine
Prescription conditions from
pharmacies Prescription
dosage form
solution for injection and infusion p7frfrdf14frd4rd14frd63 solution1414frd4f14frd414 injection and infusion
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review